An experimental targeted therapy can dramatically slow the progress of common slow-growing brain cancers, a new clinical trial finds ..read more

For women with persistent, recurrent, or metastatic cervical cancer, adding pembrolizumab to chemotherapy, with or without bevacizumab, is associated with improved overall and progression-free survival, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from June 2 to 6 in Chicago ..read more

Nationwide shortages of two dozen chemotherapy drugs are leading to rationing and delays in treatment for cancer patients, local and national authorities say ..read more

Women experience menopause at different ages—and different ways—which can, among other things, affect their heart health ..read more

A new international study published in Nature Medicine and presented as a late-breaking abstract at the American Association of Neurological Surgeons (AANS) annual conference, shows great promise for patients with glioblastoma ..read more

Gastric cancer is the fifth most commonly diagnosed malignancy worldwide. It ranks a sad third in cancer-related causes of death. The reason for this is late diagnosis coupled with rapid spread of tumor cells in the body ..read more

A recent clinical trial showed that the drug combination of cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer when compared with placebo plus platinum chemotherapy. Now an analysis published by Wiley online in Cancer, a peer-reviewed journal of the American Cancer Society, indicates that cemiplimab plus platinum chemotherapy also affects quality of life compared to chemotherapy alone ..read more

An innovative cancer drug discovered by scientists at The Institute of Cancer Research, London, is set to enter a new clinical trial ..read more

A new international study led by Monash University has, for the first time, identified that beta-blockers could significantly enhance the therapeutic effect of anthracycline chemotherapy in triple negative breast cancer (TNBC) by reducing metastasis ..read more

Immunotherapy with blinatumomab leads to a strongly improved survival rate—from 66% to 93%—for children with an aggressive form of acute lymphoblastic leukemia (ALL). They also had fewer side effects from the treatment. Based on the results, blinatumomab will now become standard treatment worldwide for babies with this aggressive form of leukemia ..read more